騰盛博藥－Ｂ
Building 7, International Science Park
3rd Floor, Zhongguancun Dongsheng No. 1 North Yongtaizhuang Road Haidian District
Beijing 100192
China
https://www.briibio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 128
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. Zhi Hong Ph.D. | Co-founder, Executive Chairman of the Board & CEO | 10.37M | 無 | 1964 |
| Dr. Ankang Li C.F.A., J.D., Ph.D. | Chief Financial & Strategy Officer, Company Secretary and Executive Director | 6.6M | 無 | 1978 |
| Dr. Eleanor de Groot Ph.D. | Chief Technology Officer | 無 | 無 | 1969 |
| Dr. Brian Alvin Johns Ph.D. | Chief Scientific Officer | 無 | 無 | 無 |
| Sarah Qiu | Associate Director of Investor Relations | 無 | 無 | 無 |
| Ms. Karen Del Barrio Neuendorff | Chief People Officer & Head of Human Resources | 無 | 無 | 1976 |
| Mr. Coy Stout | Head of Patient Advocacy | 無 | 無 | 1972 |
| Dr. Lianhong Xu Ph.D. | Head of Discovery | 無 | 無 | 1967 |
| Dr. Qing Zhu Ph.D. | Head of China Research & Development | 無 | 無 | 1968 |
| Dr. David Margolis M.D., M.P.H. | Chief Medical Officer | 無 | 無 | 1975 |
描述
Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases primarily in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trail and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. The company was incorporated in 2017 and is headquartered in Beijing, China.
公司管治
截至 無 止，騰盛博藥－Ｂ 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
